IPSS Risk Category Intermediate-1

Drug	Drug Name	Drug Description
DB15694	Cedazuridine	A cytidine deaminase inhibitor coadministered with the hypomethylating agent decitabine for the treatment of variable forms of myelodysplastic syndrome (MDS).
DB01262	Decitabine	A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression.

Drug	Drug Name	Target	Type
DB15694	Cedazuridine	Cytidine deaminase	target
DB01262	Decitabine	DNA	target
DB01262	Decitabine	DNA (cytosine-5)-methyltransferase 1	target
DB01262	Decitabine	Deoxycytidine kinase	enzyme
DB01262	Decitabine	UMP-CMP kinase	enzyme
DB01262	Decitabine	Nucleoside diphosphokinase	enzyme
DB01262	Decitabine	Cytidine deaminase	enzyme
DB01262	Decitabine	DNA (cytosine-5)-methyltransferase 3A	target
DB01262	Decitabine	DNA (cytosine-5)-methyltransferase 3B	target
DB01262	Decitabine	Sodium/nucleoside cotransporter 1	transporter
DB01262	Decitabine	Histone deacetylase	target

Drug	Drug Name	Phase	Status	Count
DB00928	Azacitidine	2	Active Not Recruiting	1
DB09037	Pembrolizumab	2	Active Not Recruiting	1